Clinical trials: Demyelinating Diseases
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This study is an extension study to the pivotal study IgPro20_3003 (NCT01545076). The purpose of this extension study is to investigate the long-term treatment of CIDP with IgPro20, with regard to safety and efficacy.
- Trial name
- NCT02027701
- Testing
- IgPro20
- Where
- 33 sites in United States, Australia and 9 more
- Volunteers
- 82 people
- Sponsor
- CSL Behring
Relapsing-Remitting Multiple Sclerosis
A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties
The purpose of this study is to determine if medication designed to improve memory will help patients with Multiple Sclerosis (MS) who are experiencing memory problems using fMRI to track brain activity.
- Trial name
- NCT00315367
- Testing
- Donepezil HCI (drug)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Neurognostics
Multiple Sclerosis
A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis
This was a US-based, observational cross-sectional study with primary data collection via questionnaires directly administered to patients with MS receiving KESIMPTA and care partners of patients with MS (formal or…
- Trial name
- NCT05334472
- Testing
- Kesimpta
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Non-Active Secondary Progressive Multiple Sclerosis
Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients
This is an open-label, intermediate-size patient population expanded access treatment study utilizing 1 dose level of nasal Foralumab (50 µg/dosing day) with the possibility of increasing to 100 µg/dosing day.
- Trial name
- NCT06802328
- Testing
- Foralumab TZLS-401 50 µg
- Where
- United States
- Sponsor
- Tiziana Life Sciences LTD
Multiple Sclerosis
BENEFIT Extension Study
To assess the long-term effects of early therapeutic intervention, i.e. within two years following a first clinical demyelinating event suggestive of MS.
- Trial name
- NCT00544037
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 18 sites in Austria, Belgium and 16 more
- Volunteers
- 283 people
- Sponsor
- Bayer
Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study
This study is a national, prospective, multicenter, non-interventional (observational) study with the aim to describe the impact of Siponimod treatment in a real-world SPMS population in Switzerland who are treated with Siponimod…
- Trial name
- SWISSMASIA (NCT04895202)
- Testing
- Siponimod
- Where
- 6 sites in Switzerland
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP
Adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) who have completed study 161403 will be able to take part in this study.
- Trial name
- NCT02955355
- Testing
- HYQVIA
- Where
- 35 sites in United States, Argentina and 16 more
- Volunteers
- 85 people
- Sponsor
- Baxalta now part of Shire
Multiple Sclerosis, Relapsing-Remitting, Clinically Isolated Syndrome
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
The purpose of this study is to further evaluate the safety and efficacy of Tovaxin in the treatment of relapsing forms of multiple sclerosis.
- Trial name
- OLTERMS (NCT00595920)
- Testing
- Tovaxin
- Where
- 27 sites in United States
- Volunteers
- 116 people
- Sponsor
- Opexa Therapeutics, Inc.
Multiple Sclerosis
Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis
Fampyra, a voltage-dependent potassium channel blocker, is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7).
- Trial name
- FAMILY (NCT03164018)
- Testing
- Fampridine
- Where
- Greece
- Volunteers
- 111 people
- Sponsor
- Genesis Pharma CNS & Specialty
Infantile Refsum's Disease, Zellweger Syndrome
Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid
OBJECTIVES: I. To Evaluate the therapeutic efficacy of cholic acid during provision of compassionate treatment to patients with identified inborn errors of bile acid synthesis and metabolism II.
- Conditions
- Infantile Refsum's Disease, Zellweger Syndrome, Adrenoleukodystrophy, Peroxisomal Disorders
- Trial name
- NCT00007020
- Testing
- Cholic Acids
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Multiple Sclerosis, Relapsing Remitting
To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients
This study is observational, non-controlled, multicentric and prospective, without experimental intervention or control. As part of the usual management of the subjects, scales will be used for the assessment of the spasticity…
- Trial name
- NCT01080040
- Where
- Argentina
- Volunteers
- 150 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing-Remitting Multiple Sclerosis (RRMS)
A Study for Tysabri Participant Preference
The primary objective of this study is to collect, evaluate and compare data on participant preference between subcutaneous (SC) and intravenous (IV) natalizumab.
- Trial name
- NCT05304520
- Testing
- Natalizumab
- Where
- 40 sites in Germany
- Volunteers
- 318 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT06408259
- Testing
- Ozanimod, Fingolimod
- Where
- 33 sites in United States, Australia and 9 more
- Volunteers
- 194 people
- Sponsor
- Bristol-Myers Squibb
Multiple Sclerosis
Efficacy and Safety of GTR in Comparison to Copaxone®
The purpose of this study is demonstrate that efficacy and safety of Synthon's glatiramer acetate (GTR) is equivalent to Copaxone® (Teva) in patients with relapsing remitting multiple sclerosis
- Trial name
- GATE (NCT01489254)
- Testing
- Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®)
- Where
- 133 sites in United States, Belarus and 17 more
- Volunteers
- 794 people
- Sponsor
- Synthon BV
Multiple Sclerosis
Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers
This study will look at differences in bioanalytical measures among different groups of MS patients and Healthy Volunteers, when administered interferon beta-1a.
- Trial name
- NCT00913666
- Testing
- Interferon beta-1a (Avonex)
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Biogen
Metachromatic Leukodystrophy (MLD)
Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)
Objectives: The overall objective is to evaluate the safety, efficacy and pharmacokinetics (PK) of rhASA treatment in patients with late infantile MLD.
- Trial name
- NCT00418561
- Testing
- rhASA - Dose Level 1, rhASA - Dose Level 2, rhASA - Dose Level 3
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Shire
NMO Spectrum Disorder
Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
The objectives of this phase Ib study are to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenic profiles of B001 in subjects with aquaporin-4 antibody (AQP4-IgG) positive NMOSD.
- Trial name
- NCT05145361
- Testing
- B001 injection
- Where
- 4 sites in China
- Volunteers
- 45 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Relapsing-Remitting Multiple Sclerosis
Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt
The purpose of this observational study is to evaluate the Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients with Relapsing-Remitting Multiple Sclerosis in Egypt
- Trial name
- NCT05423769
- Testing
- Fingolimod
- Where
- 2 sites in Egypt
- Volunteers
- 30 people
- Sponsor
- Hikma Pharmaceuticals LLC
Multiple Sclerosis
Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada
Primary Objective: To collect blood samples in a new cohort of Relapsing Forms of Multiple Sclerosis (RMS) participants who had developed immune thrombocytopenic purpura (ITP) after LEMTRADA treatment, for future Deoxyribonucleic…
- Trial name
- LEMTRADA-ITP (NCT03784898)
- Testing
- Blood draw for future biomarker analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Sclerosis
ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon
Study to evaluate efficacy of fingolimod in patients with neutralizing antibodies over 12 months
- Trial name
- ENGYNE (NCT01621269)
- Testing
- Fingolimod
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.